Transplantation clinical trials at UCSF
1 in progress, 0 open to new patients
Sorry, not yet accepting patients
The purpose of this study is to determine the safety and feasibility of converting patients to Belatacept monotherapy (receiving just one immunosuppression drug), and to see what percentage of those patients can be safely converted to once every 8 week administration of Belatacept. Belatacept has been approved by the Food and Drug Administration (FDA) for kidney transplant recipients.
Last updated: October 19, 2016